Cholinergic and GABAergic Mechanisms in the Septohippocampal Pathway
隔海马通路中的胆碱能和 GABA 能机制
基本信息
- 批准号:7579972
- 负责人:
- 金额:$ 30.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-02-01 至 2011-01-31
- 项目状态:已结题
- 来源:
- 关键词:AcetylcholineAcetylcholinesterase InhibitorsAlzheimer&aposs DiseaseBrainBrain regionCRF receptor type 1Clinical ResearchCognitionCognitive deficitsCorticotropin-Releasing Hormone ReceptorsCyclic AMPCyclic AMP-Dependent Protein KinasesCyclic GMPCyclic GMP-Dependent Protein KinasesCyclic NucleotidesDiseaseEnzymesFiberGlutamatesGuanylate CyclaseHealthHumanHydrolysisImageImageryImpaired cognitionLabelLearningLiteratureMemoryMental disordersMethodsMuscarinic Acetylcholine ReceptorNeuronsNeurotransmittersNitric OxideNitric Oxide DonorsNitric Oxide SynthaseOxidesPDE2 phosphodiesterasePathway interactionsPhosphodiesterase InhibitorsPhosphotransferasesPhysiologicalPopulationRecruitment ActivityResearch PersonnelRodentRoleSchizophreniaScopolamineSliceStressTechniquesTestingUnited Statesanalogbasecholinergiccholinergic neurondepressionnerve supplynormal agingphosphoric diester hydrolasepreventprogramsrelating to nervous systemseptohippocampal
项目摘要
DESCRIPTION (provided by applicant): Cognitive impairment is a serious health concern in the United States; it accompanies normal aging and dementing disorders such as Alzheimer's, as well as mental illnesses, such as schizophrenia and depression. Basic and clinical studies have long recognized the importance of acetylcholine (ACh) in cognition. The cholinergic muscarinic receptor antagonist, scopolamine, impairs learning and memory in humans and rodents primarily through actions on the brain septohippocampal neurons (SHNs). Acetylcholinesterase inhibitors, although limited in efficacy, are currently the best available treatment for Alzheimer's disease. The cyclic nucleotides, cAMP and cGMP, have also been implicated in learning and memory and certain phosphodiesterase (PDE) inhibitors that prevent cyclic nucleotide hydrolysis are cognitively beneficial and can also reverse scopolamine-induced cognitive deficits. While cAMP is effectively recruited by the stress-related neurotransmitter, CRF, the gaseous neural messenger, nitric oxide (NO) is the primary activator of the cGMP cascade. The SHNs, that give rise to the mnemonically important septohippocampal pathway receive CRF innervation, are endowed with CRF1 receptors and in preliminary electrophysiological studies were activated by CRF and cAMP analogs. Additionally, cholinergic SHNs belong to the unique population of CNS neurons that express the NO synthesizing enzyme. In preliminary studies GABA-type but not cholinergic-type SHNs, were activated by NO donors and cGMP analogs. NO imaging studies and PDE inhibitors also suggested the presence of a constitutive NO/cGMP tone as well as a cAMP tone in this brain region. We hypothesize that: 1) NO released from cholinergic SHNs behaves as an intercellular messenger to activate GABAergic SHNs through activation of the cGMP-kinase cascade and that cGMP actions are terminated primarily by the cGMP-specific PDE9; 2) CRF acting via CRF1 receptors and the cAMP-kinase cascade in cholinergic SHNs indirectly activates GABAergic SHNs through increased ACh release; 3) cAMP actions are terminated primarily by PDE4 and cross-talk between the cyclic nucleotide pathways occurs through dual-substrate PDE2 and possibly through a CRF-induced increase in NO synthesis. The above hypothesis will be tested using electrophysiological, immunohistochemical and NO visualization techniques in rodent brain slices.
描述(由申请人提供):认知障碍在美国是一个严重的健康问题;它伴随着正常的衰老和痴呆,如阿尔茨海默氏症,以及精神疾病,如精神分裂症和抑郁症。基础和临床研究早就认识到乙酰胆碱(ACh)在认知中的重要性。胆碱能毒蕈碱受体拮抗剂东莨菪碱主要通过作用于大脑中隔海马神经元(SHNs)来损害人类和啮齿动物的学习和记忆。乙酰胆碱酯酶抑制剂虽然疗效有限,但目前是治疗阿尔茨海默病的最佳方法。环核苷酸cAMP和cGMP也与学习和记忆有关,某些阻止环核苷酸水解的磷酸二酯酶(PDE)抑制剂对认知有益,也可以逆转东莨菪碱诱导的认知缺陷。当cAMP被应激相关的神经递质CRF(气态神经信使)有效募集时,一氧化氮(NO)是cGMP级联的主要激活剂。产生具有记忆作用的中隔海马通路的shn接受CRF神经支配,被赋予CRF1受体,在初步的电生理研究中被CRF和cAMP类似物激活。此外,胆碱能shn属于独特的中枢神经系统神经元群体,表达NO合成酶。在初步研究中,氨基丁酸型而非胆碱能型shn可被NO供体和cGMP类似物激活。NO成像研究和PDE抑制剂也提示在该脑区存在组成性NO/cGMP张力和cAMP张力。我们假设:1)胆碱能SHNs释放的NO作为细胞间信使,通过激活cGMP激酶级联激活gaba能SHNs, cGMP作用主要由cGMP特异性PDE9终止;2)在胆碱能SHNs中,CRF通过CRF1受体和camp激酶级联作用,通过增加ACh释放间接激活gaba能SHNs;3) cAMP的作用主要由PDE4终止,环核苷酸通路之间的串扰通过双底物PDE2发生,并可能通过crf诱导的NO合成增加。上述假设将通过电生理、免疫组织化学和NO可视化技术在啮齿动物脑切片上进行验证。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Meenakshi Alreja其他文献
Meenakshi Alreja的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Meenakshi Alreja', 18)}}的其他基金
CHOLINERGIC & GABAERGIC MECHANISM SEPTOHIPPOCAMPAL PATHWAY
胆碱能
- 批准号:
6694434 - 财政年份:2001
- 资助金额:
$ 30.02万 - 项目类别:
Cholinergic and GABAergic Mechanisms in the Septohippocampal Pathway
隔海马通路中的胆碱能和 GABA 能机制
- 批准号:
7368082 - 财政年份:2001
- 资助金额:
$ 30.02万 - 项目类别:
Cholinergic and GABAergic Mechanisms in the Septohippocampal Pathway
隔海马通路中的胆碱能和 GABA 能机制
- 批准号:
7766997 - 财政年份:2001
- 资助金额:
$ 30.02万 - 项目类别:
CHOLINERGIC & GABAERGIC MECHANISM SEPTOHIPPOCAMPAL PATHWAY
胆碱能
- 批准号:
6629276 - 财政年份:2001
- 资助金额:
$ 30.02万 - 项目类别:
CHOLINERGIC & GABAERGIC MECHANISM SEPTOHIPPOCAMPAL PATHWAY
胆碱能
- 批准号:
6846081 - 财政年份:2001
- 资助金额:
$ 30.02万 - 项目类别:
Cholinergic and GABAergic Mechanisms in the Septohippocampal Pathway
隔海马通路中的胆碱能和 GABA 能机制
- 批准号:
7172593 - 财政年份:2000
- 资助金额:
$ 30.02万 - 项目类别:
Cholinergic and GABAergic Mechanisms in the Septohippocampal Pathway
隔海马通路中的胆碱能和 GABA 能机制
- 批准号:
7049997 - 财政年份:2000
- 资助金额:
$ 30.02万 - 项目类别:
相似海外基金
Effect of Acetylcholinesterase inhibitors on Bone Metabolism and Fracture Risk Factors among older adults with mild to moderate Alzheimer's Disease
乙酰胆碱酯酶抑制剂对患有轻至中度阿尔茨海默病的老年人骨代谢和骨折危险因素的影响
- 批准号:
10739853 - 财政年份:2023
- 资助金额:
$ 30.02万 - 项目类别: